{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:58:59Z","timestamp":1791896339312,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA163012"],"award-info":[{"award-number":["R01CA163012"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA194511"],"award-info":[{"award-number":["R01CA194511"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA233100"],"award-info":[{"award-number":["U01CA233100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.immuni.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T11:02:26Z","timestamp":1549364546000},"page":"477-492.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["Clonal Deletion of Tumor-Specific T Cells by Interferon-\u03b3 Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade"],"prefix":"10.1016","volume":"50","author":[{"given":"Chien-Chun Steven","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanhyuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kole T.","family":"Roybal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Seagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunobu","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao X.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"DuPage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena S.","family":"Kwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Daud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Fasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Sachidanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitha","family":"Jayaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy-Jo","family":"Casbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian A.","family":"Kinsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6428-428X","authenticated-orcid":false,"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2019.01.006_bib1","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.290.5495.1354","article-title":"Regulation of antigen-specific CD8+ T\u00a0cell homeostasis by perforin and interferon-gamma","volume":"290","author":"Badovinac","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.immuni.2019.01.006_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nm1554","article-title":"IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy","volume":"13","author":"Berner","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T\u00a0cell co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2019.01.006_bib7","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2019.01.006_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in\u00a0vivo","volume":"194","author":"Das","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ccr.2010.11.011","article-title":"Endogenous T\u00a0cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression","volume":"19","author":"DuPage","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.immuni.2019.01.006_bib13","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1073\/pnas.0712269105","article-title":"SPAS-1 (stimulator of prostatic adenocarcinoma-specific T\u00a0cells)\/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade","volume":"105","author":"Fass\u00f2","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2019.01.006_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ni.3386","article-title":"Control of T\u00a0cell antigen reactivity via programmed TCR downregulation","volume":"17","author":"Gallegos","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib16","doi-asserted-by":"crossref","first-page":"e25752","DOI":"10.4161\/onci.25752","article-title":"Interferon \u03b3-induced intratumoral expression of CXCL9 alters the local distribution of T\u00a0cells following immunotherapy with Listeria monocytogenes","volume":"2","author":"Guirnalda","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.immuni.2019.01.006_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.immuni.2019.01.006_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2019.01.006_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN gamma in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.immuni.2019.01.006_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T\u00a0cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2019.01.006_bib22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.immuni.2019.01.006_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature22311","article-title":"Tumour ischaemia by interferon-\u03b3 resembles physiological blood vessel regression","volume":"545","author":"Kammertoens","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2019.01.006_bib24","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2019.01.006_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.immuni.2019.01.006_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T\u00a0cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2019.01.006_bib28","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2019.01.006_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","article-title":"Interferons and the immunogenic effects of cancer therapy","volume":"36","author":"Minn","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib31","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T\u00a0cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol."},{"key":"10.1016\/j.immuni.2019.01.006_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T\u00a0cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2019.01.006_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nprot.2014.006","article-title":"Full-length RNA-seq from single cells using Smart-seq2","volume":"9","author":"Picelli","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.immuni.2019.01.006_bib35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.20020666","article-title":"Interferon gamma is required for activation-induced death of T lymphocytes","volume":"196","author":"Refaeli","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib36","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib37","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T\u00a0cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T\u00a0cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2019.01.006_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib42","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T\u00a0cells (Tregs) in human cancers","author":"Sharma","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2019.01.006_bib43","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T\u00a0cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib45","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T\u00a0cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib46","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","article-title":"Homeostasis of naive and memory T\u00a0cells","volume":"29","author":"Surh","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2019.01.006_bib48","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T\u00a0cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2019.01.006_bib49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2019.01.006_bib50","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2019.01.006_bib51","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/jir.2009.0119","article-title":"Predominant interferon-\u03b3-mediated expression of CXCL9, CXCL10, and CCL5 proteins in the brain during chronic infection with Toxoplasma gondii in BALB\/c mice resistant to development of toxoplasmic encephalitis","volume":"30","author":"Wen","year":"2010","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.immuni.2019.01.006_bib52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T\u00a0cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4049\/jimmunol.176.1.507","article-title":"IL-15 regulates CD8+ T\u00a0cell contraction during primary infection","volume":"176","author":"Yajima","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2019.01.006_bib55","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-\u03b3 in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2019.01.006_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2019.01.006_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12859-017-1544-9","article-title":"3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T\u00a0cell repertoire data","volume":"18","author":"Zhang","year":"2017","journal-title":"BMC Bioinformatics"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761319300299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761319300299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:03:55Z","timestamp":1761033835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761319300299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1074761319300299"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2019.01.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735007057.793567353","asserted-by":"object"}]},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clonal Deletion of Tumor-Specific T Cells by Interferon-\u03b3 Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}